Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer.
Journal Information
Full Title: Ther Adv Med Oncol
Abbreviation: Ther Adv Med Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"The authors declare that there is no conflict of interest."
Funding Disclosure
Evidence found in paper:
"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This trial was sponsored by the Canadian Cancer Trials Group (CCTG), which is funded by the Canadian Cancer Society. Funding for the trial conduct and experimental drugs were provided by Astra Zeneca. Dr. Jonathan Loree and Dr. Daniel Renouf have received Michael Smith Health Professional Investigator Awards. Funding from BC Cancer Foundation helped support this analysis."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025